Research programme: biosimilars - Amphastar Pharmaceuticals
Latest Information Update: 22 Nov 2016
At a glance
- Originator Amphastar Pharmaceuticals
- Class Biological factors
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 08 Nov 2016 Preclinical trials in Undefined indication in USA before November 2016